LTZ-301

N/A

Report date: 2025/02/25 10:19:28

First In Class

Base Information

Drug NameLTZ-301

Drug Alias NameLTZ-301

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionImmunomodulatorsMacrophages stimulantsNatural killer cells stimulants +[4]

TargetsB-cell antigen receptor complex-associated protein beta chain

Therapy Area/IndicationsAutoimmune DiseasesLymphoma, Mantle-CellLymphoma, Follicular +[7]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesLTZ Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesLTZ Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsAutoimmune DiseasesLymphoma, Mantle-CellLymphoma, Follicular +[7]

Inactive IndicationsN/A

Other Information

ATC CodeN/A